Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): A randomised, open-label phase 2 trial

Mark Sulkowski, Christophe Hezode, Jan Gerstoft, John M. Vierling, Josep Mallolas, Stanislas Pol, Marcelo Kugelmas, Abel Murillo, Nina Weis, Ronald Nahass, Oren Shibolet, Lawrence Serfaty, Marc Bourliere, Edwin Dejesus, Eli Zuckerman, Frank Dutko, Melissa Shaughnessy, Peggy Hwang, Anita Y.M. Howe, Janice WahlMichael Robertson, Eliav Barr, Barbara Haber

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): A randomised, open-label phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences